Form 4: Director John Bell Receives Stock Options at Immunocore

Immunocore Holdings plc director John Irving Bell was granted 27,492 stock options as part of a standard equity compensation award.

Summary

• Director John Irving Bell was granted 27,492 share options in Immunocore Holdings plc (IMCR).
• The options have an exercise price of $28.52 per share.
• The grant date for the transaction was May 27, 2026.
• The options are set to expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• The grant aligns the director's long-term interests with those of shareholders through equity-based compensation.

Negatives

• The issuance of new options results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Immunocore's ordinary shares.

Future Outlook

The options vest on the earlier of May 27, 2027, or the day prior to the next annual general meeting, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to ensure board alignment with long-term corporate milestones and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for NASDAQ-listed biotechnology companies.
• The vesting schedule tied to the annual general meeting is a common mechanism used by life sciences firms to manage director retention.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the options on May 27, 2027, or the day prior to the next annual general meeting.

Key Dates

Keywords

Immunocore, IMCR, Form 4, Insider Trading, Stock Options, Biotech